Plain-English translation of NCT07675590 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
Researchers are testing a new medication called to see if it is safe and how your body processes it. About 18 healthy adults who are overweight or obese will take different doses of (or a placebo) by mouth every day for 4 weeks. The goal is to understand whether this medication is well-tolerated and to gather early safety information.
Obesity and being overweight affect millions of people, and there is a need for new, safe treatment options. This early-stage trial is the first step in testing whether this medication could eventually help people manage their weight.
You likely qualify if…
You likely don't qualify if…
You would visit the study center and take an assigned dose of either or placebo twice daily by mouth for 28 days. Throughout the study, researchers would monitor your safety through blood tests, vital signs, heart monitoring, and other checks. The study would likely involve multiple in-person or remote visits to track how you're doing and to make sure the medication is well-tolerated.
AI-generated summary from trial data · Jul 7, 2026 · Not medical advice
United States
Phase
Safety & dosing
Sponsor
TIXiMED, Inc.
Enrollment target
~18 participants
Started
June 2026
Primary completion
October 2026
Age range
18 Years – 70 Years
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Gloria Keopuhiwa
TIXiMED, Inc.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.